In the fight against Covid-19, the search for a vaccine is a major international effort. In addition to trying to find a vaccine for the virus, drug companies also are working to find medical treatments that could alleviate some of the symptoms of the virus and help patients to recover faster and better.
Behind the scenes, underwriters and risk engineers are involved in this effort too. We have brought our risk expertise to discussions with clients that are exploring potential vaccines and treatments or looking at adapting existing medicines to address some of the effects of Covid-19.
In this article, Christophe Durand-Maniclas, Head of Executive Underwriting, Life Science at AXA XL focuses on the complex regulatory landscape pharmaceutical companies need to navigate as they seek to develop medical treatments to combat Covid-19 and how insurance can help in the medical fight against the pandemic.